SSWM
NBIX icon

Sheets Smith Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Sheets Smith Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,159
Closed -$297K – 390
2024
Q2 		$297K Buy
2,159
+101
+5% +$13.9K 0.04% 319
2024
Q1 		$284K Buy
2,058
+9
+0.4% +$1.23K 0.03% 324
2023
Q4 		$270K Buy
+2,049
New +$236K 0.04% 295
2020
Q1 		– Sell
-5,028
Closed -$536K – 306
2019
Q4 		$536K Buy
+5,028
New +$526K 0.1% 204

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sheets Smith Wealth Management's NBIX Position: Q3 2024 in Review

Sheets Smith Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 2,159 shares — an estimated $297K sold.

Sheets Smith Wealth Management first reported a position in NBIX in Q4 2019 and held it in 4 quarters. The position peaked at $536K in Q4 2019. 575 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Sheets Smith Wealth Management reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • Sheets Smith Wealth Management sold 2,159 Neurocrine Biosciences shares in Q3 2024, an estimated $297K.
  • Sheets Smith Wealth Management first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 4 quarters.
  • Sheets Smith Wealth Management's Neurocrine Biosciences position peaked at $536K in Q4 2019.
  • 575 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Sheets Smith Wealth Management's 13F filing for Q3 2024, filed 1 Nov 2024.